查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1726269

全球糖尿病视网膜病变市场：市场规模、份额、趋势分析（按类型、管理方法和地区）、细分市场预测（2025-2030 年）

Diabetic Retinopathy Market Size, Share & Trends Analysis Report By Type (Proliferative Diabetic Retinopathy), By Management (Anti-VEGF, Intraocular Steroid Injection, Laser Surgery, Vitrectomy), By Region And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

糖尿病视网膜病变市场的成长与趋势：

根据 Grand View Research, Inc. 的最新报告，全球糖尿病视网膜病变市场预计到 2030 年将达到 137.7 亿美元，预测期内的复合年增长率为 6.4%。

各个地区糖尿病盛行率的上升以及人们对糖尿病视网膜病变 (DR) 的有效管理和有效治疗重要性的认识不断提高是主要的市场驱动力。糖尿病视网膜病变若未及时治疗，会导致严重的视力障碍，甚至失明。医疗保健基础设施的改善和现代治疗方法的增加预计将推动市场成长。

多个地区糖尿病确诊人数的大幅增加也促进了该市场的成长。此外，人们越来越意识到早期检测和有效管理血糖值的重要性，这也推动了市场的成长。此外，与糖尿病相关的失明病例增加有关的令人震惊的统计数据也在不断增加，预计这将支持该市场的成长。

根据美国糖尿病协会的报告，糖尿病患者有青光眼、白内障和黄斑部水肿等眼科疾病的风险。根据美国疾病管制与预防中心的数据，美国约有 3,840 万人患有糖尿病。

糖尿病视网膜病变市场：分析概述

  • 到 2024 年，非增生性糖尿病视网膜病变将占据市场主导地位，份额超过 70.0%。
  • 预计在预测期内，雷射手术将以最快的复合年增长率成长。
  • 抗 VEGF 管理领域在 2024 年占据最大的市场占有率，为 92.3%。
  • 医疗保健投资的增加和技术进步促进了市场的成长。
  • 由于人们认识的提高、医疗保健基础设施的完善以及抗 VEGF 药物的高市场渗透率，北美在全球市场占据主导地位。
  • 2024 年 9 月，印度国家监管机构核准了Remidio Medios DR AI，这是一款眼科 AI 软体，可促进可转诊 DR 的自动检测。

目录

第一章 分析方法与范围

第二章执行摘要

3. 糖尿病视网膜病变市场：驱动因素、趋势与范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 糖尿病视网膜病变市场：分析工具
    • 产业分析：波特五力分析
    • PESTEL分析

第四章糖尿病视网膜病变市场：按类型估计和趋势分析

  • 按类型分類的仪表板
  • 糖尿病视网膜病变市场：依类型波动分析
  • 全球糖尿病视网膜病变市场：市场规模预测与趋势分析（按类型）（2018-2030 年）
  • 增生性糖尿病视网膜病变
  • 非增生性糖尿病视网膜病变

第五章糖尿病视网膜病变市场：依管理方法的估计与趋势分析

  • 管理仪表板
  • 糖尿病视网膜病变市场：依管理方法的差异分析
  • 全球糖尿病视网膜病变市场：市场规模预测与趋势分析（按管理方法）（2018-2030 年）
  • 抗VEGF
  • 眼内类固醇注射
  • 雷射手术
  • 玻璃体切除手术

第六章糖尿病视网膜病变市场：按地区估计和趋势分析

  • 市场仪表板：按地区
  • 各地区市场占有率分析（2024 年及 2030 年）
  • 连续生物加工市场：按地区分類的关键要点
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 泰国
    • 澳洲
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要企业热力图分析（2024年）
  • 公司简介
    • Bayer AG
    • AbbVie Inc.
    • Novartis AG
    • Oxurion NV.
    • Sirnaomics, Inc.
    • Alimera Sciences
    • Ampio Pharmaceuticals Inc.
    • BCN Peptides
    • Kowa Company, Ltd.
    • Genentech, Inc.
Product Code: 978-1-68038-466-6

Diabetic Retinopathy Market Growth & Trends:

The global diabetic retinopathy market is anticipated to reach USD 13.77 billion by 2030 and expand at a CAGR of 6.4% during the forecast period, according to a new report by Grand View Research, Inc. Rising incidence of diabetes in multiple regions and growing awareness regarding the significance of efficient management and effective treatment of Diabetic Retinopathy (DR) are key market drivers. If not treated in time, DR may result in severe vision impairment or even blindness. Improved healthcare infrastructure and increasing accessibility to modern treatments are expected to fuel market growth.

The significant increase in the number of individuals diagnosed with diabetes across multiple regions contributes to growth of this market. Rising awareness regarding the importance of early detection and effective management of blood glucose levels, which reduces the chances of DR, also fuels the market growth. Furthermore, the alarming statistics related to the increasing cases of diabetes-related blindness also increase are expected to support growth of this market.

A report from the American Diabetes Association states that people with diabetes are at risk of developing eye diseases, such as glaucoma, cataracts, and macular edema. DR is considered one of the main reasons for blindness in the U.S. According to the U.S. Centers for Disease Control and Prevention, nearly 38.4 million individuals have diabetes in the U.S.

Diabetic Retinopathy Market Report Highlights:

  • Non-proliferative diabetic retinopathy dominated the market with more than 70.0% share in 2024 owing increasing awareness regarding importance of early detection and timely treatment.
  • Laser surgery is expected to grow at the fastest CAGR over the forecast period.
  • The anti-VEGF management segment held the largest market share of 92.3% in 2024.
  • The rise in healthcare investments and advancements in technology contribute to market growth.
  • North America dominated the global market owing to increasing awareness, sophisticated healthcare infrastructure, and high market penetration of anti-VEGF drugs.
  • In September 2024, India's national regulatory authority approved an ophthalmic AI software, Remidio Medios DR AI, which facilitates the automatic detection of referable DRs.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Management
    • 1.2.3. Regional Scope
    • 1.2.4. Estimates and Forecasts Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
    • 1.4.5. Details of Primary Research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type Outlook
    • 2.2.2. Management Outlook
    • 2.2.3. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. Diabetic Retinopathy Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Diabetic Retinopathy Market Analysis tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political Landscape
      • 3.3.2.2. Technological Landscape
      • 3.3.2.3. Economic Landscape

Chapter 4. Diabetic Retinopathy Market: Type Estimates & Trend Analysis

  • 4.1. Type Segment Dashboard
  • 4.2. Diabetic Retinopathy Market: Type Movement Analysis
  • 4.3. Global Diabetic Retinopathy Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Proliferative Diabetic Retinopathy
    • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.5. Non-Proliferative Diabetic Retinopathy
    • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. Diabetic Retinopathy Market: Management Estimates & Trend Analysis

  • 5.1. Management Segment Dashboard
  • 5.2. Diabetic Retinopathy Market: Management Movement Analysis
  • 5.3. Global Diabetic Retinopathy Market Size & Trend Analysis, by Management, 2018 to 2030 (USD Million)
  • 5.4. Anti-VEGF
    • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5. Intraocular Steroid Injection
    • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6. Laser Surgery
    • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.7. Vitrectomy
    • 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. Diabetic Retinopathy Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Dashboard
  • 6.2. Regional Market Share Analysis, 2024 & 2030
  • 6.3. Continuous Bioprocessing Market By Region: Key Takeaways
  • 6.4. North America
    • 6.4.1. U.S.
      • 6.4.1.1. Key Country Dynamics
      • 6.4.1.2. Regulatory Framework/ Reimbursement Structure
      • 6.4.1.3. Competitive Scenario
      • 6.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Canada
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.4.2.3. Competitive Scenario
      • 6.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Mexico
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework/ Reimbursement Structure
      • 6.4.3.3. Competitive Scenario
      • 6.4.3.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. UK
      • 6.5.1.1. Key Country Dynamics
      • 6.5.1.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.1.3. Competitive Scenario
      • 6.5.1.4. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Germany
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.2.3. Competitive Scenario
      • 6.5.2.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.3. France
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.3.3. Competitive Scenario
      • 6.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Italy
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.4.3. Competitive Scenario
      • 6.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.5. Spain
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.5.3. Competitive Scenario
      • 6.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Denmark
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.6.3. Competitive Scenario
      • 6.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.7. Sweden
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.7.3. Competitive Scenario
      • 6.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.8. Norway
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.8.3. Competitive Scenario
      • 6.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Japan
      • 6.6.1.1. Key Country Dynamics
      • 6.6.1.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.1.3. Competitive Scenario
      • 6.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.2. China
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.2.3. Competitive Scenario
      • 6.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.3. India
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.3.3. Competitive Scenario
      • 6.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.4. South Korea
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.4.3. Competitive Scenario
      • 6.6.4.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Thailand
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.5.3. Competitive Scenario
      • 6.6.5.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.6.3. Competitive Scenario
      • 6.6.6.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Brazil
      • 6.7.1.1. Key Country Dynamics
      • 6.7.1.2. Regulatory Framework/ Reimbursement Structure
      • 6.7.1.3. Competitive Scenario
      • 6.7.1.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Argentina
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.7.2.3. Competitive Scenario
      • 6.7.2.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. South Africa
      • 6.8.1.1. Key Country Dynamics
      • 6.8.1.2. Regulatory Framework/ Reimbursement Structure
      • 6.8.1.3. Competitive Scenario
      • 6.8.1.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.2. Saudi Arabia
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.8.2.3. Competitive Scenario
      • 6.8.2.4. Saudi Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.3. UAE
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework/ Reimbursement Structure
      • 6.8.3.3. Competitive Scenario
      • 6.8.3.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.4. Kuwait
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework/ Reimbursement Structure
      • 6.8.4.3. Competitive Scenario
      • 6.8.4.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. Key Company Heat Map Analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. Bayer AG
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. AbbVie Inc.
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Novartis AG
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Oxurion NV.
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. Sirnaomics, Inc.
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. Alimera Sciences
      • 7.4.6.1. Company Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Ampio Pharmaceuticals Inc.
      • 7.4.7.1. Company Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. BCN Peptides
      • 7.4.8.1. Company Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Kowa Company, Ltd.
      • 7.4.9.1. Company Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. Genentech, Inc.
      • 7.4.10.1. Company Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America diabetic retinopathy market, by country, 2018 - 2030 (USD Million)
  • Table 3 North America diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 4 North America diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 5 U.S. diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 6 U.S. diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 7 Canada diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 8 Canada diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 9 Mexico diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 10 Mexico diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 11 Europe diabetic retinopathy market, by country, 2018 - 2030 (USD Million)
  • Table 12 Europe diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 13 Europe diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 14 UK diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 15 UK diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 16 Germany diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 17 Germany diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 18 France diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 19 France diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 20 Italy diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 21 Italy diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 22 Spain diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 23 Spain diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 24 Denmark diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 25 Denmark diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 26 Sweden diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 27 Sweden diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 28 Norway diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 29 Norway diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific diabetic retinopathy market, by country, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 33 Japan diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 34 Japan diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 35 China diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 36 China diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 37 India diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 38 India diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 39 South Korea diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 40 South Korea diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 41 Thailand diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 42 Thailand diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 43 Australia diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 44 Australia diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 45 Latin America diabetic retinopathy market, by country, 2018 - 2030 (USD Million)
  • Table 46 Latin America diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 47 Latin America surgical ablation market, by management, 2018 - 2030 (USD Million)
  • Table 48 Brazil diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 49 Brazil diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 50 Argentina diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 51 Argentina diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 52 MEA diabetic retinopathy market, by country, 2018 - 2030 (USD Million)
  • Table 53 MEA diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 54 MEA diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 55 South Africa diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 56 South Africa diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 59 UAE diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 60 UAE diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 61 Kuwait diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 62 Kuwait diabetic retinopathy market, by management, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Diabetic retinopathy market: market outlook
  • Fig. 10 Diabetic retinopathy competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 Diabetic retinopathy market driver impact
  • Fig. 16 Diabetic retinopathy market restraint impact
  • Fig. 17 Diabetic retinopathy market strategic initiatives analysis
  • Fig. 18 Diabetic retinopathy market: Type movement analysis
  • Fig. 19 Diabetic retinopathy market: Type outlook and key takeaways
  • Fig. 20 Proliferative diabetic retinopathy market estimates and forecast, 2018 - 2030
  • Fig. 21 Non-proliferative diabetic retinopathy estimates and forecast, 2018 - 2030
  • Fig. 22 Diabetic retinopathy market: Management movement analysis
  • Fig. 23 Diabetic retinopathy market: Management outlook and key takeaways
  • Fig. 24 Anti-VEGF market estimates and forecasts, 2018 - 2030
  • Fig. 25 Intraocular steroid injection market estimates and forecasts,2018 - 2030
  • Fig. 26 Laser surgery market estimates and forecasts, 2018 - 2030
  • Fig. 27 Vitrectomy market estimates and forecasts, 2018 - 2030
  • Fig. 28 Global diabetic retinopathy market: regional movement analysis
  • Fig. 29 Global diabetic retinopathy market: regional outlook and key takeaways
  • Fig. 30 North America market estimates and forecasts, 2018 - 2030
  • Fig. 31 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 32 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 33 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 34 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 35 UK market estimates and forecasts, 2018 - 2030
  • Fig. 36 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 37 France market estimates and forecasts, 2018 - 2030
  • Fig. 38 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 39 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 40 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 41 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 42 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 43 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 44 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 45 China market estimates and forecasts, 2018 - 2030
  • Fig. 46 India market estimates and forecasts, 2018 - 2030
  • Fig. 47 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 48 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 49 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 50 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 51 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 52 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 53 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 54 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 55 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 56 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 57 Kuwait market estimates and forecasts, 2018 - 2030